Targeted agents for the treatment of metastatic melanoma

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 31-46

  Monzon, Jose G ^a   Dancey, Janet ^a  

^a Queen's Cancer Research Institute   (Canada)

Author keywords

Antitumor; Ipilimumab; Metastatic melanoma; Vemurafenib

Indexed keywords

B RAF KINASE INHIBITOR; CARBOPLATIN; CHIR 265; DACARBAZINE; GSK 436; INTERLEUKIN 2; IPILIMUMAB; MAMMALIAN TARGET OF RAPAMYCIN; MELANOCYTE PROTEIN PMEL 17; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MOLECULAR MARKER; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PACLITAXEL; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SELUMETINIB; SORAFENIB; STEM CELL FACTOR RECEPTOR; TEMOZOLOMIDE; TRAMETINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEMURAFENIB; ZELBORAFR;

ALOPECIA; ARTHRALGIA; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CENTRAL SEROUS RETINOPATHY; DIARRHEA; DRUG TARGETING; ENZYME ACTIVATION; FATIGUE; HUMAN; IMMUNE RESPONSE; KERATOACANTHOMA; MELANOMA; MOLECULAR PATHOLOGY; NAUSEA; NONHUMAN; PATIENT SELECTION; PHOTOSENSITIVITY; RASH; RECOMMENDED DRUG DOSE; RETINA VEIN OCCLUSION; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME; TUMOR IMMUNITY;

EID: 84861398281     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S21259     Document Type: Review

References (136)

1. American Cancer Society. Cancer Facts and Figures 2011. 2011:1-60. Available from: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2011. Accessed January 16, 2012.
2. Canadian Cancer Society. Canadian Cancer Statistics 2011. 2011:1-133. Available from: http://www.cancer.ca. Accessed January 16, 2012.
3. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3635-3648.
4. De Vita V, Hellman S, Rosenberg S. Biologic Therapy of Cancer: Melanoma. Philadelphia, PA: Lippincott; 1995:388-411.
5. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6 Suppl 1:S11-S14.
6. Cipponi A, Wieers G, van Baren N, Coulie PG. Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why? Cancer Immunol Immunother. 2011;60(8):1153-1160.
7. Hadrup SR, Bakker AH, Shu CJ, et al. Parallel detection of antigenspecific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods. 2009;6(7):520-526.
8. Kalialis LV, Drzewiecki KT, Klyver H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 2009;19(5):275-282.
9. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother. 2004;53(10):844-854.
10. Krasagakis K, Thölke D, Farthmann B, et al. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer. 1998;77(9):1492-1494.
11. Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Eng J Med. 2008;358(25):2698-2703.
12. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
13. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Eng J Med. 2011;364(26):2517-2526.
14. Harris NL, Ronchese F. The role of B7 costimulation in T-cell immunity. Immunol Cell Biol. 1999;77(4):304-311.
15. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engd J Med. 2011;364(26):2507-2516.
16. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene. 2007;26(22):3100-3112.
17. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell. 2004;6(4):313-319.
18. Lange-Carter CA, Johnson GL. Ras-dependent growth factor regulation of MEK kinase in PC12 cells. Science. 1994;265(5177):1458-1461.
19. Marais R, Light Y, Paterson HF, Marshall CJ. Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 1995;14(13):3136-3145.
20. Minden A, Lin A, McMahon M, et al. Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science. 1994;266(5191):1719-1723.
21. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem. 1997;272(7):4378-4383.
22. Mason CS, Springer CJ, Cooper RG, et al. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J. 1999;18(8):2137-2148.
23. Xu S, Robbins D, Frost J, et al. MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase. Pro Nat Acad Sci U S A. 1995;92(15):6808-6812.
24. Cohen C, Zavala-Pompa A, Sequeira JH, et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res. 2002;8(12):3728-3733.
25. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
26. Omholt K, Karsberg S, Platz A, et al. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res. 2002;8(11):3468-3474.
27. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19-20.
28. Emuss V, Garnett M, Mason C, Marais R. Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res. 2005;65(21):9719-9726.
29. Pritchard CA, Samuels ML, Bosch E, McMahon M. Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol. 1995;15(11):6430-6442.
30. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Pro Nat Acad Sci U S A. 2008;105(8):3041-3046.
31. Barbacid M. ras genes. Annu Rev Biochem. 1987;56:779-827.
32. Whitwam T, Vanbrocklin MW, Russo ME, et al. Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene. 2007;26(31):4563-4570.
33. Ball NJ, Yohn JJ, Morelli JG, et al. Ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol. 1994;102(3):285-290.
34. van Elsas A, Zerp S, van der Flier S, et al. Analysis of N-ras mutations in human cutaneous melanoma: tumor heterogeneity detected by polymerase chain reaction/single-stranded conformation polymorphism analysis. Recent Results Cancer Res. 1995;139:57-67.
35. Cully M, You H, Levine AJ, Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006;6(3):184-192.
36. Robertson GP. Functional and therapeutic signif icance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 2005;24(2):273-285.
37. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004;64(19): 7002-7010.
38. Zhou XP, Gimm O, Hampel H, et al. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol. 2000;157(4):1123-1128.
39. Yamada KM, Araki M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci. 2001;114(Pt 13): 2375-2382.
40. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005;4(12):988-1004.
41. Tsao H, Mihm MC Jr, Sheehan C. PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma. J Am A Dermatol. 2003;49(5):865-872.
42. Whiteman DC, Zhou XP, Cummings MC, et al. Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer. 2002;99(1):63-67.
43. Wu H, Goel V, Haluska FG. PTEN signaling pathways in melanoma. Oncogene. 2003;22(20):3113-3122.
44. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. New Eng J Med. 2005;353(20):2135-2147.
45. Slipicevic A, Holm R, Nguyen MT, et al. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am J Clin Pathol. 2005;124(4):528-536.
46. Meier F, Schittek B, Busch S, et al. The RAS/RAF/MEK/ERK and PI3K/ AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci. 2005;10:2986-3001.
47. Cheung M, Sharma A, Madhunapantula SV, Robertson GP. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res. 2008;68(9):3429-3439.
48. Hemesath TJ, Price ER, Takemoto C, Badalian T, Fisher DE. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature. 1998;391(6664):298-301.
49. Roskoski R Jr. Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor. Biochem Biophys Res Commun. 2005;338(3):1307-1315.
50. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147.
51. Ashida A, Takata M, Murata H, Kido K, Saida T. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer. 2009;124(4):862-868.
52. Jiang X, Zhou J, Yuen NK, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008;14(23):7726-7732.
53. Handolias D, Salemi R, Murray W, et al. Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. Pigment Cell Melanoma Res. 2010;23(2):210-215.
54. Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res. 2011;17(7): 1684-1691.
55. Yun J, Lee J, Jang J, et al. KIT amplification and gene mutations in acral/mucosal melanoma in Korea. APMIS. 2011;119(6):330-335.
56. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9): 809-819.
57. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Cur Opin Oncol. 2011;23(2):177-182.
58. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol. 2009;27(23):e59-e61.
59. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010;140(2):209-221.
60. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010;464(7287):431-435.
61. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010;464(7287):427-430.
62. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 2010;468(7326):968-972.
63. Paraiso KH, Xiang Y, Rebecca VW, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71(7):2750-2760.
64. Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977.
65. Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683-695.
66. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-3096.
67. Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol. 2011;12(9):913-922.
68. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors [abstract]. ASCO Annual Meeting. 2010:8503.
69. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research. 2004;64(19):7099-7109.
70. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612.
71. Ahmad T, Marais R, Pyle L, et al. BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience [abstract]. ASCO Annual Meeting. 2004:7506.
72. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006;95(5):581-586.
73. Flaherty K, Brose M, Schuchter L, et al. Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma [abstract]. ASCO Annual Meeting. 2004:7507.
74. Flaherty KT, Lee SJ, Schuchter LM, et al. Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma [abstract]. ASCO Annual Meeting. 2010:8511.
75. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009;27(17):2823-2830.
76. Sharfman WH, Hodi FS, Lawrence DP, et al. Results from the first-inhuman (FIH) phase I study of the oral RAF inhibitor RAF265 administered daily to patients with advanced cutaneous melanoma [abstract]. ASCO Annual Meeting. 2011:8508.
77. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2006;439(7074):358-362.
78. LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res. 2010;16(6):1924-1937.
79. Boasberg PD, Redfern CH, Daniels GA, et al. Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer. Cancer Chemother Pharmacol. 2011;68(2):547-552.
80. Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res. 2011;17(5):989-1000.
81. Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212 [abstract]. ASCO Annual Meeting. 2010:2503.
82. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogenactivated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13(5):1576-1583.
83. Dummer R, Robert C, Chapman PB, et al. AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study [abstract]. ASCO Annual Meeting. 2008:9033.
84. Dry JR, Pavey S, Pratilas C a, et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 2010;70(6):2264-2273.
85. Pratilas CA, Taylor BS, Ye Q, et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Nat Acad Sci U S A. 2009;106(11):4519-4524.
86. Ernst DS, Eisenhauer E, Wainman N, et al. Phase II study of perifosine in previously untreated patients with metastatic melanoma. Invest New Drugs. 2005;23(6):569-575.
87. Burris HA, Siu LL, Infante JR, et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study [abstract]. Asco Annual Meeting. 2011:3003.
88. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Nat Acad Sci U S A. 2001;98(18):10314-10319.
89. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103(2):253-262.
90. Gera JF, Mellinghoff IK, Shi Y, et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Bio Chem. 2004;279(4):2737-2746.
91. Margolin K, Longmate J, Baratta T, et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer. 2005;104(5):1045-1048.
92. Rao RD, Windschitl HE, Allred JB, et al. Phase II trial of the mTOR inhibitor everolimus (RAD-001) in metastatic melanoma [abstract]. ASCO Annual Meeting. 2006:8043.
93. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol. 2007;25(12):1606-1620.
94. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methylphenyl)- 2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin- 4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47(27):6658-6661.
95. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
96. Pavlů J, Marin D. Dasatinib and chronic myeloid leukemia: twoyear follow-up in eight clinical trials. Clin Lymphoma Myeloma. 2009;9(6):417-424.
97. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011;12(9):841-851.
98. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127-1134.
99. von Mehren M. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. Clin Colorectal Cancer. 2006;6 Suppl 1:S30-S34.
100. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011;305(22):2327-2334.
101. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol. 2011;29(21):2904-2909.
102. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008;99(5): 734-740.
103. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer. 2005;92(8):1398-1405.
104. Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer. 2006;106(9):2005-2011.
105. Kluger HM, Dudek AZ, McCann C, et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer. 2011;117(10):2202-2208.
106. Kalinsky K, Lee SJ, Lawrence DP, Kirkwood JM. A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607) [abstract]. ASCO Annual Meeting. 2010:TPS312.
107. Assistance Publique - Hôpitaux de Paris. Efficacy of nilotinib in first or second line treatment of primary melanomas stage III unresectable melanomas. (NILOMEL). In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated February 7, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01168050.NLMidentifier:NCT01168050. Accessed February 8, 2012.
108. Dana-Farber Cancer Institute. Nilotinib in TKI resistant or intolerant patients with metastatic mucosal, acral, or chronically sun damaged melanoma. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2008 [updated October 27, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00788775.NLMidentifier:NCT00788775. Accessed February 8, 2012.
109. Institute of Cancer Research, United Kingdom. A trial looking at nilotinib to treat acral and mucosal melanoma skin cancer that has spread (NICAM). In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2011 [updated July 14, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01395121.NLMidentifier:NCT01395121. Accessed February 8, 2012.
110. Novartis Pharmaceuticals. A study of AMNN107 in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation (TEAM). In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2009 [updated August 11, 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT01028222.NLMidentifier:NCT01028222. Accessed February 8, 2012.
111. Samsung Medical Center. Study of nilotinib in metastatic melanoma with KIT aberrations. In: ClinicalTrials.gov [website on the Internet]. Bethseda, MD: US National Library of Medicine; 2010 [updated January 10, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01099514.NLMidentifier:NCT01099514. Accessed February 8, 2012.
112. Kim KB, Davies MA, Papadopoulos NE, et al. Phase I/II study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma [abstract]. ASCO Annual Meeting. 2009:9026.
113. Sebti SM, Adjei AA. Farnesyltransferase inhibitors. Semin Oncol. 2004;31(1 Suppl 1):S28-S39.
114. Chow LQ, Eckhardt SG, O'Bryant CL, et al. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008;62(4):631-646.
115. Gajewski TF, Niedzwiecki D, Johnson J, et al. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma: CALGB 500104 [abstract]. ASCO Annual Meeting. 2006:8014.
116. Lipton A, Ready N, Bukowski RM, et al. Phase I study of continuous oral lonafarnib plus weekly paclitaxel for advanced cancer [abstract]. ASCO Annual Meeting. 2002:364.
117. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000;18(4):927-941.
118. Hong DS, Sebti SM, Newman RA, et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009;15(22):7061-7068.
119. Margolin KA, Moon J, Flaherty LE, et al. Randomized phase II trial of sorafenib (SO) with temsirolimus (TEM) or tipifarnib (TIPI) in metastatic melanoma: Southwest Oncology Group Trial S0438 [abstract]. ASCO Annual Meeting. 2010:8502.
120. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001;19(2):577-583.
121. Hainsworth JD, Spigel DR, Burris 3rd HA, et al. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010;28(13):2131-2136.
122. Hainsworth JD, Infante JR, Spigel DR, et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer. 2010;116(17):4122-4129.
123. Hodi FS, Friedlander PA, Atkins MB, et al. A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma [abstract]. ASCO Annual Meeting. 2011:8511.
124. Schoenfeld J, Jinushi M, Nakazaki Y, et al. Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010;70(24):10150-10160.
125. Infante JR, Falchook GS, Lawrence DP, et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) [abstract]. ASCO Annual Meeting. 2011:CRA8503.
126. Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [abstract]. ASCO Annual Meeting. 2008:LBA9011.
127. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of singleagent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167-3175.
128. Sznol M, Hodi FS, Margolin K, et al. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA) [absract]. ASCO Annual Meeting. 2008:3007.
129. Kruit WH, Suciu S, Dreno B, et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: A randomized open-label phase II study of the EORTC Melanoma Group (16032-18031) [abstract]. ASCO Annual Meeting. 2008:9065.
130. Schwartzentruber DJ, Lawson DH, Richards JM, et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119-2127.
131. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009;27(34): 5763-5771.
132. Kaufman HL, Kim DW, DeRaffele G, et al. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann Surg Oncol. 2010;17(3):718-730.
133. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res. 2007;13(6):1801-1809.
134. Hauschild A, Gutzmer R, Ugurel S, et al. Sorafenib and pegylated interferon-alpha-2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Ann Oncol. 2011;22(7):1667-1674.
135. McDermott DF, Sosman JA, Gonzalez R, et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol. 2008;26(13):2178-2185.
136. Eisen T, Marais R, Affolter A, et al. An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma [abstract]. ASCO Annual Meeting. 2007:8529.